Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | GLA | P06280 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559896 | 1.00 | KDM4E (0.49) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL22858208 | 0.78 | CDK4 (0.41) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL22866493 | 0.75 | KDM4E (0.38) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL29559825 | 0.75 | KDM4E (0.38) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL23502945 | 0.69 | AR (0.42) | — | |
| SCHEMBL20670865 | 0.67 | XDH (0.35) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL562812 | 0.66 | KDM4E (1.00) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL16858459 | 0.66 | KDM4E (0.44) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL29560609 | 0.66 | PARP1 (0.51) | ALDH1A1 | |
| SCHEMBL23503139 | 0.66 | AR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-04-06 | — | — | US | disclosed |
| EP-3994139-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | Effector Therapeutics Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114269756-A | 4-oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds inhibiting EIF4E | 效应疗法股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EFFECTOR THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EIF4E, EIF4EBP1, EIF4A1 | KDM4E 393/4885ALDH1A1 4794/4885HPGD 4854/4885 |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | EIF4E, EIF4EBP1, EIF4A1 | KDM4E 393/4885ALDH1A1 4794/4885HPGD 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.